Novartis AG (NVSN) - Total Assets
Based on the latest financial reports, Novartis AG (NVSN) holds total assets worth MX$118.53 Billion MXN (≈ $6.82 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Novartis AG to assess how comfortably operating cash covers total debt obligations.
Novartis AG - Total Assets Trend (2014–2025)
This chart illustrates how Novartis AG's total assets have evolved over time, based on quarterly financial data. See NVSN book value for net asset value and shareholders' equity analysis.
Novartis AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Novartis AG's total assets of MX$118.53 Billion consist of 27.5% current assets and 72.6% non-current assets.
| Asset Category | Amount (MXN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 10.3% |
| Accounts Receivable | MX$8.94 Billion | 8.1% |
| Inventory | MX$6.27 Billion | 5.7% |
| Property, Plant & Equipment | MX$0.00 | 0.0% |
| Intangible Assets | MX$29.41 Billion | 26.5% |
| Goodwill | MX$25.57 Billion | 23.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Novartis AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Novartis AG worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novartis AG's current assets represent 27.5% of total assets in 2025, a decrease from 30.0% in 2014.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2025, down from 10.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 40.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 26.5% of total assets.
Novartis AG Competitors by Total Assets
Key competitors of Novartis AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Roche Holding AG
SW:RO
|
Switzerland | CHF100.70 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
|
China | CN¥41.14 Billion |
Novartis AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.85 | 0.79 | 0.80 |
| Quick Ratio | 0.65 | 0.61 | 0.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | MX$-4.77 Billion | MX$-6.51 Billion | MX$-5.83 Billion |
Novartis AG - Advanced Valuation Insights
This section examines the relationship between Novartis AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.26 |
| Latest Market Cap to Assets Ratio | 2.68 |
| Asset Growth Rate (YoY) | 8.5% |
| Total Assets | MX$110.95 Billion |
| Market Capitalization | $297.59 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Novartis AG's assets at a significant premium (2.68x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Novartis AG's assets grew by 8.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Novartis AG (2014–2025)
The table below shows the annual total assets of Novartis AG from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | MX$110.95 Billion ≈ $6.39 Billion |
+8.51% |
| 2024-12-31 | MX$102.25 Billion ≈ $5.88 Billion |
+2.30% |
| 2023-12-31 | MX$99.94 Billion ≈ $5.75 Billion |
-14.91% |
| 2022-12-31 | MX$117.45 Billion ≈ $6.76 Billion |
-10.88% |
| 2021-12-31 | MX$131.79 Billion ≈ $7.58 Billion |
-0.20% |
| 2020-12-31 | MX$132.06 Billion ≈ $7.60 Billion |
+11.56% |
| 2019-12-31 | MX$118.37 Billion ≈ $6.81 Billion |
-18.68% |
| 2018-12-31 | MX$145.56 Billion ≈ $8.38 Billion |
+9.38% |
| 2017-12-31 | MX$133.08 Billion ≈ $7.66 Billion |
+2.27% |
| 2016-12-31 | MX$130.12 Billion ≈ $7.49 Billion |
-1.09% |
| 2015-12-31 | MX$131.56 Billion ≈ $7.57 Billion |
+4.92% |
| 2014-12-31 | MX$125.39 Billion ≈ $7.22 Billion |
-- |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more